NVDA
Not just a rich checkbook
Nvidia loves to show up in headlines as the company behind the check. But according to Generate Biomedicines co-founder and CTO Gevorg Grigoryan, the chip giant’s bigger value is the stuff you can’t tally on a balance sheet: technical know-how, performance tuning, and a deep playbook for wringing more out of accelerated computing.
That’s a fancy way of saying Nvidia isn’t just handing over money and waving goodbye. It’s helping Generate figure out how to run very heavy biological AI workloads more efficiently, which is kind of the whole game when your models are chewing through mountains of data to design and evaluate potential medicines.
Why investors should care
This is the kind of setup that turns Nvidia from a hardware supplier into a platform enabler. If AI is the new electricity, Nvidia is trying to be the person who also installs the wiring, the transformer, and maybe even the smart thermostat.
For biotech, that means a company like Generate can scale its models without hitting the computational version of a traffic jam. For Nvidia, it’s another example of how its reach expands when customers don’t just buy GPUs — they also lean on the company’s software expertise and optimization muscle.
The bigger picture
The takeaway isn’t that Nvidia and Generate have announced some giant new commercial contract. It’s that Nvidia’s moat may be widening in a quieter, nerdier way: by becoming the go-to technical partner for companies trying to make AI useful in the real world.
Big picture: if Nvidia keeps embedding itself this deeply into the workflows of AI-native companies, it’s not just selling picks and shovels anymore — it’s helping design the mine.